BetterLife Pharma names Charles Duncan audit committee chair, appoints him director

Reuters2026/09/11 10:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BetterLife Pharma appointed Charles Duncan, PhD, to its board as audit committee chair.
Duncan is managing director and head of biotech strategy and development at Gilmartin Group, advising life sciences companies.
He is a former Wall Street biotechnology analyst, previously a managing director and senior analyst at Cantor Fitzgerald, Piper Jaffray, JMP Securities.
Duncan also serves on the board of Vanda Pharmaceuticals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-005526), on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BetterLife Pharma names Charles Duncan audit committee chair, appoints him director

You may also like

Crypto prices